A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
5 Articles
5 Articles
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 has highlighted the vulnerability of a globally connected population to zoonotic viruses. The FDA-approved coronavirus antiviral Paxlovid targets the essential SARS-CoV-2 main protease, Mpro. Whilst effective in the acute phase of a COVID infection, Paxlovid cannot be used by all patients, can lead to viral recurrence, and does not protect against post-acute sequelae of COVID-19 (PASC), …
UK’s first long Covid anti-viral drug trials underway five years on
A ground-breaking research project looking to find a treatment for symptoms of long Covid is underway, as the nation marks five years since the start of the pandemic.The £1.25m trial, which is the first of its kind in the UK and led by the University of Derby, is exploring whether anti-viral medications can be used as an effective treatment option for patients diagnosed with long Covid.It is estimated that over two million people in the UK and m…
New COVID-19 pill shows strong protection against tougher virus strains
Scientists at Rutgers Health have developed a new COVID-19 drug that could be a powerful alternative to Paxlovid, the most commonly used oral treatment for the virus. This new drug, called Jun13296, may solve some of the biggest problems with current treatments—especially for people who take other medications. The research, led by Professor Jun Wang […] The post New COVID-19 pill shows strong protection against tougher virus strains appeared fir…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage